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doi:10.1016/j.jtcvs.2003.09.049TBackground: Cell implantation into areas of myocardial infarction (cellular
cardiomyoplasty) may be limited in efficacy because of the lack of blood supply
to these areas of myocardium, resulting in early loss of transplanted cells. We
therefore tested the hypothesis that pretreatment of infarcted myocardium with
angiogenic therapy, followed by cell transplant, would be more effective than
the application of either strategy alone.
Methods: Fischer 344 rats underwent left coronary artery ligation and injection
of an adenovirus encoding VEGF 121, an empty expression cassette control
vector, or saline solution. Capillary density in the infarcted region was deter-
mined in preliminary studies. Cardiomyocytes harvested from syngeneic Fi-
scher rat fetuses were prelabeled and then injected directly into the infarct area
3 weeks after vector administration. Exercise treadmill testing was performed 2
weeks after cell transplantation, after which a cell viability index was calculated as
the number of implanted (prelabeled) nuclei divided by the number of coadminis-
tered microspheres detected in sections of implanted myocardium.
Results: Capillary density in the area of infarction was significantly greater in
adenovirus encoding VEGF 121 compared with rats injected with saline solution
(P  .001). The cell survival index was also greater in adenovirus encoding VEGF
121 compared with animals injected with empty expression cassette control or saline
solution (P  .0045). Exercise tolerance was nearly doubled in animals receiving
adenovirus encoding VEGF 121 3 weeks prior to cell implantation compared with
animals receiving adenovirus encoding VEGF 121 or cells alone or those receiving
adenovirus encoding VEGF 121 at the time of cell implantation (P  .001).
Conclusions: Pretreatment of an infarcted region of the heart with angiogenic
mediators such as VEGF can enhance the efficacy of cellular cardiomyoplasty,
presumably by creating a more favorable environment for the survival of trans-
planted cells.
Therapeutic angiogenesis describes the strategy wherein naturallyoccurring growth factors or progenitor cells are administered toischemic tissues to induce the formation of new blood vessels thatcan restore perfusion to ischemic tissues.1,2 The potential for angio-genic therapy to restore ventricular function is predicated upon thepresence of a substrate of contractile, or at least hibernating, cardi-
omyocytes. In contrast, reperfusion of scarred, infarcted myocardium is unlikely to
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sence of viable myocytes in this tissue. In such circum-
stances, it has been demonstrated in numerous animal stud-
ies that cellular cardiomyoplasty, wherein reserve cells such
as skeletal myoblasts, fetal cardiomyocytes, embryonic
stem cells, or bone marrow stem cells are implanted into
myocardial scar, can arrest or reverse ventricular remodel-
ing and improve myocardial function.3-13 In this therapy,
the implanted cells, which are typically harvested autog-
enously and expanded in culture, essentially “repopulate”
the area of nonfunctioning myocardial scar with viable
myocytes. Based on these findings, several dozen individ-
uals have now undergone cellular cardiomyoplasty in phase
I clinical trials.14,15
Despite these encouraging initial results, it appears that a
great number of cells do not survive implantation into areas
of infarcted myocardium.16-18 This loss of cells is not un-
expected given the unresolved ischemia in the area of in-
farction into which the reserve cells are typically implant-
ed.16-18 Under such conditions, implanted cells would
theoretically undergo necrosis or apoptosis and replacement
by fibroblasts and scar, similar to the fate of the cells
originally occupying the same ischemic territory. Possibly
on this basis, improvements in ventricular performance
noted in cellular cardiomyoplasty studies have thus far been
somewhat modest, on the order of 10% to 30%.3-13
We hypothesized that cell loss could be limited and the
results of cellular cardiomyoplasty improved by pretreating
the area of infarction with angiogenic therapy to improve
the perfusion to this scar tissue prior to cell implantation.
Accordingly, we demonstrated that angiogenic pretreatment
of scar tissue 3 weeks prior to syngeneic fetal cardiomyo-
cyte implantation in a rat coronary ligation model enhances
vascularization of the scar, improves the viability of subse-
quently implanted cells, and enhances functional improve-
ment of animals compared with results following cell ther-
apy alone.
Methods
Model Preparation and Vector Administration
Adult male Fischer 344 rats (275-300 g; Harlan; Indianapolis, Ind)
were treated in accordance with protocols approved by our Insti-
tutional Animal Care and Use Committee. The animals were
anesthetized with intraperitoneal ketamine/xylazine (85/12 mg/kg
body weight), intubated, and placed on a rodent ventilator (Har-
vard Apparatus, Holliston, Mass). A left thoracotomy was then
performed in the fourth intercostal space, and the left coronary
artery was identified and ligated 1 to 2 mm from its origin using a
7-0 polypropylene suture. At this time, 5 uniformly distributed
20-L injections each containing 2.0  109 pu (1.0  1010 total
dose) of replication defective adenovirus encoding for the 121
amino acid isoform of vascular endothelial growth factor (Ad-
VEGF), an adenovirus with an empty expression cassette (AdNull)
prepared as previously described,19,20 or an equal volume of
phosphate-buffered saline solution (PBS) were administered into
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the animal was allowed to recover under supervision. Buprenex
was administered subcutaneously (0.65 mg/kg body weight)
shortly after extubation to provide analgesia.
Immunohistochemical Analysis of Vascularization
In preliminary experiments, myocardial histologic analysis was
performed 3 weeks after animals underwent coronary ligation and
myocardial injection of AdVEGF or PBS (n  6/group). The
animals were killed with a pentobarbital overdose; the hearts were
excised and fixed using zinc-formalin prior to paraffin embedding.
Sections taken at 100-m intervals with a 5-m thickness were
prepared for immunohistochemistry utilizing a fluorescein-labeled
lectin (Galanthus Nivalis lectin, Vector Laboratories, Burlingame,
Calif). The sections were then analyzed at 200 in a blinded
manner using Metamorph Software (Universal Imaging, Downing-
town, Pa), and capillary density was calculated for each animal
from 2 fields randomly selected from each of 5 sections of in-
farcted myocardium.
Isolation of Fetal Cardiomyocytes
Gestation day 20 fetuses were harvested from syngeneic Fischer
344 rats, and their hearts were excised, washed in cold ethanol, and
stored in cold Ack Lysing Buffer (BioSource International, Cam-
arillo, Calif). The hearts were then minced and cardiomyocytes
were isolated as previously described.18 Cardiomyocyte isolation
was verified by detection of cell contractions 24 hours after initial
plating. Harvested cells were expanded in Dulbecco’s modified
Eagle’s medium-F12 media with 10% fetal bovine serum, insulin-
transferrin-selenium, and penicillin-streptomycin (Gibco BRL,
Grand Island, NY) at 37°C (5% CO2) for no more than 10 days, or
until they were 90% confluent.18
Fetal Cardiomyocyte Preparation
Fetal cardiomyocytes expanded in culture as described above were
suspended using trypsin 0.025%/ethylenediaminetetraacetic acid
(Gibco BRL), and then collected in PBS. The cells were then
treated with a 1-mol solution of Hoechst 33342 (Sigma, St Louis,
Mo), a blue fluorescent DNA intercalator, and incubated at 37°C in
5% CO2 for 15 minutes. The cells were subjected to 3 washes with
5 the initial media volume and then allowed to recover for 45
minutes in growth media. The cells were then collected and cen-
trifuged, and aliquots of 1.5  106 cells were resuspended in 100
L of PBS. An aliquot of 1  106 red fluorescent 2.0-m micro-
spheres (Molecular Probes, Eugene, Ore), prepared according to
manufacturer’s specifications, was added to each fetal cardiomy-
ocyte preparation as an internal standard for accuracy of myocar-
dial delivery and sampling efficiency (final injectate cell:sphere
ratio, 1.5:1). Prior to myocardial injection, a small sample was
aspirated from the cell preparation and added to an equal volume
of 0.4% trypan blue (Sigma), which was then assayed in a hemo-
cytometer to determine cell viability.
In separate experiments, similarly prepared cells were heat-
treated (65°C for 15 minutes) or treated at 37°C for 15 minutes
with 100 mol/L of the apoptotic agent valinomycin (Sigma),
according to manufacturer’s specifications, to verify that the de-
tection of nuclear staining could not be attributed to the staining of
nonviable cells. These cells were first demonstrated to be nonvi-
il 2004
Retuerto et al Cardiopulmonary Support and Physiology
CS
Pable utilizing flow cytometry analysis of an aliquot of cells labeled
with a vital dye (LIVE/DEAD Viability Kit, Molecular Probes),
according to the manufacturer’s specifications (data not shown).
Similarly treated cells were then administered into normal hearts
utilizing the injection technique described below.
Fetal Cardiomyocyte Administration
A second left lateral thoracotomy was performed 3 weeks after the
initial coronary ligation and vector administration. The region of
myocardial infarction was identified as a grayish-white area on the
anterolateral surface of the left ventricle (occupying approximately
20%-30% of the entire left ventricle). Five equidistant 20-L
injections of PBS or the cell mixtures described above were then
delivered subepicardially throughout the infarcted myocardium. In
an additional set of animals that initially received PBS at the time
of coronary ligation, both AdVEGF and cells were administered at
the time of second thoracotomy. The chest was then closed and
postoperative care was performed as described for the first oper-
ation.
Exercise Tolerance Testing
All animals were trained prior to the time of initial operation by
running for 10 minutes at a constant speed of 15 m/min on a
multitrack small-animal motorized treadmill (Model 42-15, Quin-
ton, Bothell, Wash). Immediately prior to the second operation
(and cell implantation) and again 2 weeks later, the animals were
exercised to the point of exhaustion (10 falls/min) on the same
treadmill according to a standardized protocol, as follows: 10
m/min for 5 minutes, 15 m/min for 5 minutes, and 25 m/min for
the remainder of the treadmill protocol.21
Cell Survival Analysis
Immediately following the final exercise tolerance testing, all
animals were anesthetized in an isofluorane chamber and killed
using a lethal dose of pentobarbital. The hearts were then har-
vested, washed in saline solution, and fixed in zinc-formalin for 24
hours, as previously described.22 The ventricles were then cut into
3 equal transverse sections and prepared by frozen sectioning for
analytical microscopy of unstained or hematoxylin and eosin–
stained serial sections. Fifteen cross sections of the infarcted
Figure 1. Vessel number (mean  standard deviation
following the direct myocardial injection of AdVEGF or
group).region taken at 100-m intervals and a sectioning thickness of 7
The Journal of Thoracicm were imaged using a Leica DMIRB microscope (Wetzler,
Germany) and a Spot RT digital camera (Diagnostic Instrument
Inc, Sterling Heights, Calif). Five fields per animal were analyzed
in a blinded fashion at 400 with Metamorph Software using a red
and blue fluorescence filter set (Chroma, Brattleboro, Vt). A cell
survival index was calculated for each image as the ratio of total
number of detected (fluorescent) nuclei divided by the total num-
ber of detected microspheres, and a mean cell survival ratio was
calculated for each animal (AdVEGF: n 9; AdNull: n 5; PBS:
n  7).
Statistical Analysis
Data are expressed as means and standard deviations. Analysis of
variance was used to show significance; post-hoc tests with Bon-
ferroni correction were used for pairwise comparisons.
Results
Scar Angiogenesis
The ability of angiogenic therapy to induce vascularization
in areas of myocardial scar was analyzed in preliminary
experiments. Vessel number was determined in sections of
infarcted myocardium obtained 3 weeks following the direct
myocardial injection of AdVEGF or saline solution at the
time of coronary ligation (Figure 1). An almost twofold
increase in capillary density was observed in the area of
infarction in animals receiving the AdVEGF treatment com-
pared with saline-injected animals (550  80 vs 290  70
capillaries/mm2, respectively, P  .001).
Cell Culture and Purity
Primary harvest of fetal cardiomyocytes yielded approxi-
mately 1  105 cells per fetal heart after expansion in
culture over 7 to 10 days. Cell viability was estimated to be
95% to 99% based upon trypan blue staining of an aliquot
of cells sampled just prior to cell transplantation. Approxi-
mately 80% to 90% of cultured cells were determined to be
cardiomyocytes based upon a typical triangular, loosely
oriented pattern of cells demonstrating spontaneous syn-
sections of infarcted myocardium obtained 3 weeks
ne solution at the time of coronary ligation (n  6 per) in
salichronized contractions (Figure 2).
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In additional preliminary experiments, myocardial sections
were obtained 2 weeks after the injection of heat- or vali-
nomycin-treated fetal cardiomyocytes that had been prela-
beled with a blue fluorescent marker to verify that the
detection of this marker could not be attributed to the
persistent labeling of nonviable cell implants. Essentially no
heat-treated cells and only sparse valinomycin-treated cells,
with severely deformed and pyknotic nuclei, were detected
in these sections. In contrast, more than 50 intact cells per
section with normal-appearing circular nuclei were detected
after implantation of an equivalent number of untreated
cells into normal myocardium.
Based upon these preliminary studies, preadministration
of a blue fluorescent nuclear dye was used to mark fetal
cardiomyocytes prior to their implantation into areas of
myocardial infarction. Areas of transmural scar into which
these cells were implanted were readily identifiable by the
gross morphology of hearts harvested 5 weeks after coro-
nary ligation (Figure 3). Histologic analysis of these tissues
in some cases demonstrated nearly transmural deposition of
cells implanted into these tissues (Figure 4). The pattern of
blue fluorescence observed in these sections was consistent
morphologically with the presence of cell implants (Figure
5).
To quantitatively evaluate the potential ability of pread-
ministration of angiogenic agents to enhance the survival of
implanted cells, we devised a cell survival index represent-
ing the ratio of (prelabeled) blue fluorescent implanted cell
nuclei divided by the number of coadministered micro-
spheres seen in the same sections (Figure 6, A). This ratio
was used to correct for variability in cell injection and
Figure 2. Photomicrographs (200) of cultured cells approxi-
mately 10 days after primary harvest from fetal hearts showing a
typical triangular, loosely oriented pattern of fetal cardiomyo-
cytes.sampling (Table 1). The cell survival index in sections of
1044 The Journal of Thoracic and Cardiovascular Surgery ● Aprinfarcted myocardium obtained 2 weeks after fetal cardio-
myocyte implantation and 5 weeks after VEGF, AdNull, or
saline solution administration was 4.7 3.0, 1.0  0.9, and
1.9 1.4 (P .0045) for these groups, respectively (Figure
6, B).
Exercise Tolerance
Exercise tolerance was significantly prolonged in animals
receiving AdVEGF 3 weeks prior to fetal cardiomyocyte
implantation (at the time of coronary ligation) compared
with animals receiving AdNull or saline solution at the time
of coronary ligation or receiving delayed AdVEGF admin-
istration at the time of cell implantation (Figure 7; AdVEGF
[n  4]: 29  4 minutes; AdNull [n  8]: 16  4 minutes;
saline solution [n  4]: 15  2 minutes; “delayed” Ad-
VEGF [n  4]: 16  1 minutes; P  .001). Animals that
received saline solution alone instead of cell implantation at
the time of second operation also demonstrated a shorter
exercise tolerance time compared with the cell-implanted
animals (AdVEGF/“no cells” [n  3]: 17  1 minutes;
AdNull/“no cells” [n  5]: 14  2 minutes, respectively; P
 .001 compared with AdVEGF/cells).
Discussion
Cellular cardiomyoplasty represents a novel alternative to
conventional mechanical and surgical strategies for the
functional enhancement of extensively infarcted myocar-
dium. Although cellular cardiomyoplasty is already being
investigated in clinical trials,14,15 much remains unknown
about this new therapy. For example, although acute postin-
farction inflammation has been cited as limiting cell sur-
vival following implantation, we and others have speculated
that persistent ischemia in the infarct territory was another
potential contributor to implanted cell loss that could con-
16-18
Figure 3. Gross morphology of myocardial scar and typical region
of interest (circle).sequently limit the efficacy of this therapy. Supporting
il 2004
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Pthis hypothesis, angiogenic therapy given prior to cell im-
plantation is demonstrated in the present study to improve:
(1) vascularization of the infarct territory, (2) implanted cell
survival, and (3) exercise performance.
Cellular cardiomyoplasty performed with or without the
concomitant administration of angiogenic therapy has been
previously reported to improve ventricular function in nu-
merous previous postinfarct studies.3-13,16-18,23-26 The im-
provements in exercise performance noted in the present
study suggest the potential importance of angiogenic pre-
treatment as an adjunct to cellular cardiomyoplasty, al-
though differences in the efficacy parameters employed and
uncertainties regarding surviving cell implant number make
direct comparisons between this and prior studies difficult.
The potential importance of angiogenic pretreatment in
avoiding an “ischemic interval” that may adversely affect
cell survival and the consequent functional benefits of cel-
lular cardiomyoplasty has already been noted by Sakakibara
and colleagues,27 who administered basic fibroblast growth
factor–incorporating microspheres 1 week prior to fetal
cardiomyocyte transplantation in a rat coronary ligation
model. These investigators concluded that “prevasculariza-
tion” enhances the benefits of cellular cardiomyoplasty, but
only relatively small improvements in ventricular function
and no data in regard to cell survival were reported in this
study.
In contrast to the studies of the Kyoto group, we allowed
an interval of 3 weeks between the delivery of angiogenic
agents and cell implantation, based upon our prior observa-
tions of the time intervals required for maximal blood vessel
development following growth factor administration.28 The
present data do not exclude the possibility that shorter time
intervals might not adequately provide for the development
of a nutritive vasculature to support cell implantation in
Figure 4. Photomicrographs (40) of area of cell a
fluorescence (right panel) imaging demonstrating traninfarcted territories. The present studies also do not exclude
The Journal of Thoracicthe potential role of the vasodilator or antiapoptotic prop-
erties of VEGF in enhancing the survival of cells implanted
at these shorter intervals, although the lack of improvement
noted in the “concomitant cell/AdVEGF” group in the
present studies suggest that these properties are less impor-
tant than “prevascularization” in enhancing the efficacy of
cellular cardiomyoplasty.
Aside from the appropriate timing of angiogenic pre-
treatment prior to cellular cardiomyoplasty, it is interesting
to speculate as to the extent of revascularization needed to
maximize the results of this therapy. The approximate dou-
bling in vascularization observed in AdVEGF versus nega-
tive control animals in the present study was consistent with
a similar increase in cell survival measured in these animals.
Conceivably, the observed increase in cell survival in the
present study occurred as a result of a corresponding in-
crease in perfusion of the infarcted tissues into which the
cells were injected, as predicted by prior studies correlating
the vascularization and perfusion of myocardial scar tis-
sue.24 Although the dose of angiogenic vector administered
in the present study was calculated, based upon prior phar-
macokinetic studies,28,29 to yield a maximal angiogenic
effect, it will need to be further investigated to determine
whether more extensive scar revascularization would result
in even better hemodynamic results following cellular car-
diomyoplasty. Similarly, the role of enhanced perfusion in
increasing the function of implanted cells, rather than only
affecting implanted cell survival, needs to be investigated.
The potential importance of improved perfusion in en-
hancing the results of cellular cardiomyoplasty also does not
discount the potential role of postinfarct inflammation or
other stresses, such as physical strain during and after in-
jection or cell washout through the vasculature or lymphat-
ics, in negatively impacting net cell implantation efficien-
16-18,29
istration utilizing bright field (left panel) and blue
al implantation.dmincies. In this regard, the therapeutic regimen utilized
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implanted at a time point relatively remote from the point of
coronary ligation to avoid the potentially deleterious effects
of inflammation on cell survival.16-18 It is possible that cell
implantation more proximate to the time of acute myocar-
dial infarction might diminish the relevance of the current
findings. On the other hand, it is likely that optimized
delivery techniques could further enhance successful cell
implantation.
The relatively robust, transmural repopulation of the
infarct area with implanted cells achieved in this and several
Figure 5. A, Photomicrographs (200) within scar re
nuclei. B, Corresponding hematoxylin and eosin (H&
demonstrate blue fluorescence in corresponding sectiother studies suggest that it is possible to create an anatomic
1046 The Journal of Thoracic and Cardiovascular Surgery ● Aprsubstrate sufficient to support improved ventricular hemo-
dynamics. It is has not yet been demonstrated, however, that
cells implanted into infarcted myocardium retain or develop
contractile properties. Consequently, it has been suggested
that the apparent efficacy of cellular cardiomyoplasty is
related to the ability of cell implantation to improve the
elastic or compliance properties of compromised ventricles
or to prevent myocardial dilatation through the buttressing
of myocardial segments thinned by infarction.30
It has alternatively been suggested that the angiogenic
potential of the implanted cells, rather than the cellular
of interest depicting blue fluorescent implanted cell
ection. C, H&E preparation of section that did not
not shown).gion
E) ssubstrate itself, may play an important role in the observed
il 2004
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studies.5,23-26,30-32 The relative lack of benefit observed in
animals receiving angiogenic treatment without cell transfer
in this and other studies23-26 is not surprising given the
relatively large area of infarction typical of these models,
although it is interesting to note that a small but nonsignif-
icant improvement in exercise performance was noted in the
AdVEGF/“no cell” group compared with the negative con-
trol “no cell” animals. These data suggest, however, that cell
implantation, rather than angiogenic therapy, is the critical
therapeutic modality in improving the performance of al-
ready infarcted ventricles.
Assuming that the importance of angiogenic pretreat-
ment in cellular cardiomyoplasty relates to improvements in
cell survival, it is possible that ischemic cell loss might be
overcome simply by increasing the “dose” of implanted
cells. Thus, if a final dose of 1 billion cells are needed for
effective cellular cardiomyoplasty, an initial dose of 100
billion cells at a 99% cell loss without angiogenic therapy
might be as effective as a delivered dose of 20 billion cells
with pretreatment. Such high doses, however, might chal-
lenge the efficiencies of cell culture and the limitations of
Figure 6. A, Photomicrographs (400) of blue fluoresc
coinjected to delineate the area of cell administratio
deviation) after fetal cardiomyocyte implantation andvolume of injection into the scar. Furthermore, it is possible
The Journal of Thoracicthat only a finite number of cells, as compared to a percent-
age of injected cells, may survive in the ischemic environ-
ment of the infarcted myocardium. These considerations
notwithstanding, it is important to note that the optimal cell
“dose” for cellular cardiomyoplasty has not yet been deter-
mined.
There are several other limitations to the present study
that need to be considered. First, although prior studies have
TABLE 1. Cell survival index
Implanted
cell nuclei* Microspheres†
Cell
survival
index‡
Saline solution 810 730 390 230 1.9 1.4
AdNull 490 140 540 140 1.0 0.9
AdVEGF 1550 1400 330 160 4.7 3.0§
AdNull, Empty expression cassette control vector; AdVEGF, adenovirus
encoding VEGF 121.
*Total number of blue-stained nuclei detected as described in Methods.
†Total number of microspheres detected as described in Methods.
‡Calculated as cell nuclei/microspheres as detected in Methods.
§P  .0045 vs other groups.
planted cell nuclei (left panel) and red microspheres
ght panel). B, Cell survival index (mean  standard
us treatments.ent im
n (ri
variocorrelated ventricular function and the exercise performance
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studies will be needed to confirm that the improvements in
exercise tolerance noted in the present study are specifically
attributable to changes in ventricular performance. Second,
it is possible that the results of the present study are an
artifact of a specific sensitivity of the fetal cardiomyocytes
employed in the present study to ischemia, for which studies
of cell types such as myoblasts that are potentially “hardier”
than fetal cardiomyocytes are being planned. In this regard,
it should be noted that the findings of the present study as
yet apply only to cell implantation into areas of scar and
may not be extrapolated, for example, to cell implantation
into the infarct border zone, where ischemia may not play an
important role in implanted cell survival. Finally, our find-
ing of minimal benefits derived from the use of cells alone,
which is inconsistent with prior work, may be a conse-
quence of the potentially rigorous demands of the exercise
performance assay utilized in these studies and/or the po-
tential vulnerability of fetal cardiomyocytes to ischemic
conditions. Planned studies utilizing different cell types and
more direct ventricular function assays should also address
these issues.
Although progress in the development of cellular cardio-
myoplasty as a clinically relevant therapy is encouraging,
many questions remain to be answered, including such
issues as appropriate cell dose and cell type, mechanisms of
action, and even timing of implantation. The findings of the
present study provide potentially useful data regarding the
importance of angiogenic pretreatment in optimizing the
delivery of cellular cardiomyoplasty. Should the conclusion
Figure 7. Exercise tolerance (mean  standard devia
myocyte implantation (P < .001, AdVEGF/cells vs all oof the present study be proven correct, minimally invasive
1048 The Journal of Thoracic and Cardiovascular Surgery ● Aprtechniques such as catheter-based angiogenic treatments
will likely be needed before such combined therapies will
be clinically applicable for the treatment of acute or chronic
myocardial infarction.
We thank B. Cushing for help in preparation of the manuscript.
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Discussion
Dr Richard Weisel (Toronto, Ontario, Canada). Dr Rosengart, I
would like to ask what you believe would be the appropriate
indication for your combined cell and gene therapy. Your previous
work on angiogenic gene therapy was aimed at patients who have
jeopardized but viable myocardium. Cell transplantation has been
reserved for patients who have a completed infarction without
viable myocardium at risk. Patients with an extensive infarction
with thinning and dilatation are probably candidates for ventricular
restoration rather than cell or gene therapy. Therefore, angiogenic
pretreatment may be adequate treatment for patients who have
viable myocardium. Angiogenic pretreatment in patients with no
viable myocardium may improve cell survival and enhance the
benefit associated with cell transplantation. What are your thoughts
on the spectrum of patients who will require treatment?
I wanted to ask you about what indications you see for this
combined therapy. The work that you had previously done dem-
onstrated very nicely that angiogenic therapy is probably very
beneficial for those people who cannot undergo the classic revas-
cularization strategies but have viable myocardium that is jeopar-
dized. Cell transplant as we indicated has been used for those
people who have no viability that you can demonstrate on any test
in a region that you also can’t revascularize. Of course the limi-
tation with that, as we suggested, was that if the area is already
thinned and dilated you probably should whack it out rather than
putting cells into it, so now you are putting the 2 together. You are
obviously crossing the boundaries, which is likely where our
treatment is, because we seldom know for sure whether the pa-
tients have adequate viability or not after they have had an infarc-
tion. Particularly if they don’t have an aneurysm, then they prob-
ably have viable muscle, so where do you see the treatments of
angiogenic therapy, cell therapy, or the combination working into
that situation? Obviously if you already had some vascularity, you
wouldn’t need angiogenic therapy, but the majority of patients
don’t have adequate revascularization so some of them could be
done with just angiogenic therapy, some with a combination, and
some may need to have a biodegradable patch put in rather than
cell therapy. What are your thoughts on this spectrum that we need
to treat?
Dr Rosengart. Thank you, Dr Weisel. I would think that areas
that are completely infarcted and that can’t be resected would
certainly be appropriate for cell transplant. If there is a significant
amount of ischemia, and eventually we may be able to develop an
appropriate index for that, we may have to pretreat with angiogenic
therapy. I think it will be interesting to see with additional studies
whether or not you really need to pretreat in all cases as opposed
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CSPto administering cells, untransfected with angiogenic agents. The-
oretically, you would expect that by the time transplanted angio-
genic cells can induce a blood supply they would have already
been subjected to the risk for necrosis, so pretreatment is poten-
tially appealing in terms of improving cell survival. I think there
will probably be a spectrum wherein most patients will get a
combination. I think that the patients with purely ischemic disease
would just get angiogenic therapy, either as gene or protein therapy
or potentially cells as these appear to be angiogenic as well.
Patients who are on the other end of the spectrum with large
infarctions are going to need cell transplant with or without an-
giogenic pretreatment, and certainly some of this will be per-
formed via catheter-based technique.
1050 The Journal of Thoracic and Cardiovascular Surgery ● AprUnidentified speaker. Todd, I have a quick question. How did
you arrive at the 3-week interval? Is that empiric?
Dr Rosengart. That is really based on a number of our initial
studies where it would appear at least in our hands that induced
neovascularization plateaus at about 3 weeks. There is at least 1
other study looking at this concept reported by Professor Komeda
of the Kyoto group where pretreatment was performed 1 week
pre-implant. This study did show some benefit and it will be
interesting to see if this holds true, whether there is an ideal time
to wait and whether 1 week is adequate, or whether it would be
appropriate to wait for 3 weeks between angiogenic therapy and
all.Thank you.
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